ME01480B - DERIVATI 5-AMIN0-2,4,7-TRIOKS0-3,4,7,8-TETRAHIDR0-2H-PIRID0[2,3-d]PIRIMIDINA I SRODNI SPOJEVI, NAMIJENJENI LIJEČENJU RAKA - Google Patents
DERIVATI 5-AMIN0-2,4,7-TRIOKS0-3,4,7,8-TETRAHIDR0-2H-PIRID0[2,3-d]PIRIMIDINA I SRODNI SPOJEVI, NAMIJENJENI LIJEČENJU RAKAInfo
- Publication number
- ME01480B ME01480B MEP-2012-138A MEP13812A ME01480B ME 01480 B ME01480 B ME 01480B ME P13812 A MEP13812 A ME P13812A ME 01480 B ME01480 B ME 01480B
- Authority
- ME
- Montenegro
- Prior art keywords
- group
- alkyl group
- hydrogen atom
- different
- same
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract 96
- 238000011282 treatment Methods 0.000 title claims abstract 6
- 206010028980 Neoplasm Diseases 0.000 title claims abstract 4
- 201000011510 cancer Diseases 0.000 title abstract 2
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 title 1
- 150000003230 pyrimidines Chemical class 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims abstract 29
- 239000002246 antineoplastic agent Substances 0.000 claims abstract 8
- 239000008177 pharmaceutical agent Substances 0.000 claims abstract 7
- 230000000259 anti-tumor effect Effects 0.000 claims abstract 6
- -1 pyrimidine compound Chemical class 0.000 claims abstract 5
- 230000004663 cell proliferation Effects 0.000 claims abstract 4
- 201000010099 disease Diseases 0.000 claims abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 188
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 142
- 125000000623 heterocyclic group Chemical group 0.000 claims 98
- 229910052799 carbon Inorganic materials 0.000 claims 64
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 56
- 125000001424 substituent group Chemical group 0.000 claims 52
- 150000001721 carbon Chemical group 0.000 claims 24
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 24
- 125000005842 heteroatom Chemical group 0.000 claims 23
- 229920006395 saturated elastomer Polymers 0.000 claims 23
- 125000004430 oxygen atom Chemical group O* 0.000 claims 22
- 125000004434 sulfur atom Chemical group 0.000 claims 22
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 19
- 125000004093 cyano group Chemical group *C#N 0.000 claims 18
- 125000005843 halogen group Chemical group 0.000 claims 18
- 239000012453 solvate Substances 0.000 claims 16
- 229910052739 hydrogen Inorganic materials 0.000 claims 15
- 239000001257 hydrogen Substances 0.000 claims 15
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 13
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 12
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims 12
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims 12
- 239000004480 active ingredient Substances 0.000 claims 12
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 12
- 125000004429 atom Chemical group 0.000 claims 11
- 238000000034 method Methods 0.000 claims 10
- 238000004519 manufacturing process Methods 0.000 claims 9
- 125000004043 oxo group Chemical group O=* 0.000 claims 6
- 229910052717 sulfur Inorganic materials 0.000 claims 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 229910052757 nitrogen Inorganic materials 0.000 claims 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 3
- 101100310920 Caenorhabditis elegans sra-2 gene Proteins 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000002947 alkylene group Chemical group 0.000 claims 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims 1
- 102100025055 NTF2-related export protein 1 Human genes 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 230000022131 cell cycle Effects 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 239000011593 sulfur Substances 0.000 claims 1
- 125000005951 trifluoromethanesulfonyloxy group Chemical group 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 abstract 2
- 239000002168 alkylating agent Substances 0.000 abstract 1
- 229940100198 alkylating agent Drugs 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 230000003356 anti-rheumatic effect Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000004060 metabolic process Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Addiction (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- AIDS & HIV (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004174770 | 2004-06-11 | ||
| JP2004327111 | 2004-11-10 | ||
| EP10013055.8A EP2298768B9 (en) | 2004-06-11 | 2005-06-10 | 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2H-pyrido[2,3-d]pyrimidine derivatives and related compounds for the treatment of cancer |
| PCT/JP2005/011082 WO2005121142A1 (en) | 2004-06-11 | 2005-06-10 | 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2h-pyrido’2,3-d! pyrimidine derivatives and related compounds for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME01480B true ME01480B (me) | 2014-04-20 |
Family
ID=34970318
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2012-138A ME01480B (me) | 2004-06-11 | 2005-06-10 | DERIVATI 5-AMIN0-2,4,7-TRIOKS0-3,4,7,8-TETRAHIDR0-2H-PIRID0[2,3-d]PIRIMIDINA I SRODNI SPOJEVI, NAMIJENJENI LIJEČENJU RAKA |
Country Status (27)
| Country | Link |
|---|---|
| EP (3) | EP1894932A1 (OSRAM) |
| JP (3) | JP4163738B2 (OSRAM) |
| KR (1) | KR100883289B1 (OSRAM) |
| CN (2) | CN101006086B (OSRAM) |
| AT (1) | ATE383360T1 (OSRAM) |
| AU (1) | AU2005252110B2 (OSRAM) |
| BR (1) | BRPI0511967B8 (OSRAM) |
| CA (2) | CA2727841A1 (OSRAM) |
| CY (3) | CY1107253T1 (OSRAM) |
| DE (1) | DE602005004286T2 (OSRAM) |
| DK (2) | DK1761528T3 (OSRAM) |
| ES (2) | ES2297723T3 (OSRAM) |
| FR (1) | FR14C0083I2 (OSRAM) |
| HR (2) | HRP20080018T3 (OSRAM) |
| IL (1) | IL179671A0 (OSRAM) |
| LU (1) | LU92602I2 (OSRAM) |
| ME (1) | ME01480B (OSRAM) |
| MX (1) | MXPA06014478A (OSRAM) |
| NL (1) | NL300701I1 (OSRAM) |
| NO (2) | NO338355B1 (OSRAM) |
| NZ (1) | NZ552090A (OSRAM) |
| PL (2) | PL2298768T3 (OSRAM) |
| PT (2) | PT1761528E (OSRAM) |
| RS (2) | RS50569B (OSRAM) |
| RU (1) | RU2364596C2 (OSRAM) |
| SI (2) | SI1761528T1 (OSRAM) |
| WO (1) | WO2005121142A1 (OSRAM) |
Families Citing this family (188)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1912636B1 (en) * | 2005-07-21 | 2014-06-25 | Ardea Biosciences, Inc. | N-(arylamino)-sulfonamide inhibitors of mek |
| US8101799B2 (en) | 2005-07-21 | 2012-01-24 | Ardea Biosciences | Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK |
| US7919598B2 (en) * | 2006-06-28 | 2011-04-05 | Bristol-Myers Squibb Company | Crystal structures of SGLT2 inhibitors and processes for preparing same |
| JO2985B1 (ar) | 2006-12-20 | 2016-09-05 | Takeda Pharmaceuticals Co | مثبطات كينازmapk/erk |
| ES2320955B1 (es) | 2007-03-02 | 2010-03-16 | Laboratorios Almirall S.A. | Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida. |
| EP2150544B1 (en) | 2007-03-19 | 2016-01-13 | Takeda Pharmaceutical Company Limited | Mapk/erk kinase inhibitors |
| ES2329639B1 (es) | 2007-04-26 | 2010-09-23 | Laboratorios Almirall S.A. | Nuevos derivados de 4,8-difenilpoliazanaftaleno. |
| WO2009014100A1 (ja) * | 2007-07-20 | 2009-01-29 | Chugai Seiyaku Kabushiki Kaisha | ｐ２７蛋白質誘導剤 |
| WO2009064675A1 (en) * | 2007-11-12 | 2009-05-22 | Takeda Pharmaceutical Company Limited | Mapk/erk kinase inhibitors |
| WO2009146034A2 (en) * | 2008-03-31 | 2009-12-03 | Takeda Pharmaceutical Company Limited | Mapk/erk kinase inhibitors and methods of use thereof |
| EP2108641A1 (en) | 2008-04-11 | 2009-10-14 | Laboratorios Almirall, S.A. | New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors |
| EP2113503A1 (en) | 2008-04-28 | 2009-11-04 | Laboratorios Almirall, S.A. | New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors |
| UA103319C2 (en) | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
| RU2393157C1 (ru) * | 2008-10-06 | 2010-06-27 | Андрей Александрович Иващенко | 2-АЛКИЛАМИНО-3-АРИЛСУЛЬФОНИЛ-ПИРАЗОЛО[1,5-а]ПИРИМИДИНЫ, АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-HT6 РЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ |
| RU2399621C2 (ru) * | 2008-10-14 | 2010-09-20 | Андрей Александрович Иващенко | ЗАМЕЩЕННЫЕ 2-АЛКИЛАМИНО-3-СУЛЬФОНИЛ-ПИРАЗОЛО[1,5-a]ПИРИМИДИНЫ, АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-HT6 РЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ |
| ES2399384T3 (es) | 2008-11-10 | 2013-04-01 | Bayer Schering Pharma Ag | Sulfonamido fenoxibenzamidas sustituidas |
| EP2362775B1 (en) | 2008-11-20 | 2015-08-05 | GlaxoSmithKline LLC | Chemical compounds |
| EP2370568B1 (en) | 2008-12-10 | 2017-07-19 | Dana-Farber Cancer Institute, Inc. | Mek mutations conferring resistance to mek inhibitors |
| JP2012521411A (ja) * | 2009-03-26 | 2012-09-13 | マピ ファーマ リミテッド | アログリプチンの調製プロセス |
| CN101619063B (zh) * | 2009-06-02 | 2011-08-10 | 华中师范大学 | 具有抗肿瘤活性的3,7,8-多取代吡啶并[4,3-d]嘧啶衍生物及制备 |
| WO2011031308A1 (en) * | 2009-09-09 | 2011-03-17 | Cytokinetics, Incorporated | Novel combinations |
| SG179144A1 (en) * | 2009-09-23 | 2012-05-30 | Glaxosmithkline Llc | Combination |
| ES2527625T3 (es) * | 2009-09-23 | 2015-01-27 | Glaxosmithkline Llc | Combinación farmacéutica |
| AU2010298020B8 (en) * | 2009-09-28 | 2013-10-10 | Glaxosmithkline Llc | Combination |
| PT2485593E (pt) * | 2009-10-08 | 2015-04-28 | Glaxosmithkline Llc | Associação |
| PL3560498T3 (pl) | 2009-10-16 | 2022-12-12 | Novartis Ag | Kombinacja zawierająca inhibitor mek i inhibitor b-raf |
| CA2777071A1 (en) | 2009-10-21 | 2011-04-28 | Bayer Pharma Aktiengesellschaft | Substituted halophenoxybenzamide derivatives |
| US20120269803A1 (en) | 2009-10-21 | 2012-10-25 | Bayer Intellectual Property Gmbh | Substituted benzosulphonamides |
| US8962606B2 (en) | 2009-10-21 | 2015-02-24 | Bayer Intellectual Property Gmbh | Substituted benzosulphonamides |
| BR112012011677A8 (pt) * | 2009-11-17 | 2018-06-12 | Glaxosmithkline Llc | Combinação, kit de combinação e uso de uma combinação |
| MX340392B (es) | 2010-02-25 | 2016-07-06 | Dana Farber Cancer Inst Inc | Mutaciones del protooncogen de serina/treonina-proteina cinasa b-raf (braf) que confieren resistencia a los inhibidores del protooncogen de serina/treonina-proteina cinasa b-raf. |
| RU2421456C1 (ru) * | 2010-02-26 | 2011-06-20 | Общество С Ограниченной Ответственностью "Инновационная Фармацевтика" | ЗАМЕЩЕННЫЕ 3-АРИЛСУЛЬФОНИЛ-ПИРАЗОЛО[1,5-a]ПИРИМИДИН-2,6-ДИАМИНЫ, АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-НТ6 РЕЦЕПТОРОВ, СПОСОБЫ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ |
| JP5985401B2 (ja) | 2010-03-09 | 2016-09-06 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | 第一の癌療法に対する耐性を現に有するか、または、そのような耐性を生じる患者において癌を診断および治療する方法 |
| UY33288A (es) * | 2010-03-25 | 2011-10-31 | Glaxosmithkline Llc | Derivados de indolina inhibidores de la proteina quinasa r del reticulo endoplasmatico |
| US8598156B2 (en) | 2010-03-25 | 2013-12-03 | Glaxosmithkline Llc | Chemical compounds |
| AU2011240735B2 (en) * | 2010-04-13 | 2015-01-29 | Novartis Ag | Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase (CDK4/6) inhibitor and an mTOR inhibitor for treating cancer |
| US9180129B2 (en) | 2010-05-21 | 2015-11-10 | Novartis Ag | Combination of lapatinib and trametinib |
| UA112517C2 (uk) | 2010-07-06 | 2016-09-26 | Новартіс Аг | Тетрагідропіридопіримідинові похідні |
| EP2608790A4 (en) * | 2010-08-26 | 2014-04-02 | Glaxosmithkline Llc | PHARMACEUTICAL COMBINATION OF A VEGFR-INHIBITOR AND A MEK-INHIBITOR FOR THE TREATMENT OF CANCER |
| WO2012055953A1 (en) | 2010-10-29 | 2012-05-03 | Bayer Pharma Aktiengesellschaft | Substituted phenoxypyridines |
| CN102020651B (zh) | 2010-11-02 | 2012-07-18 | 北京赛林泰医药技术有限公司 | 6-芳基氨基吡啶酮甲酰胺mek抑制剂 |
| JP2014505658A (ja) * | 2010-11-05 | 2014-03-06 | グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッド | 癌を治療する方法 |
| EP2640390A4 (en) * | 2010-11-17 | 2014-08-06 | Glaxosmithkline Ip No 2 Ltd | METHODS OF TREATING CANCER |
| BR112013012485A2 (pt) * | 2010-11-19 | 2016-09-06 | Glaxosmithkline Ip No 2 Ltd | método de tratamento com inibidor braf |
| JP6063871B2 (ja) * | 2010-12-20 | 2017-01-18 | ノバルティス アーゲー | 組合せ |
| TWI505828B (zh) | 2010-12-20 | 2015-11-01 | 葛蘭素史克智慧財產（第二）有限公司 | 新穎醫藥組成物 |
| US8754114B2 (en) | 2010-12-22 | 2014-06-17 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
| WO2013019620A2 (en) * | 2011-07-29 | 2013-02-07 | Glaxosmithkline Llc | Method of treating cancer using combination of braf inhibitor, mek inhibitor, and anti-ctla-4 antibody |
| TWI835048B (zh) * | 2011-08-01 | 2024-03-11 | 美商建南德克公司 | 利用pd-1軸結合拮抗劑及mek抑制劑治療癌症之方法 |
| EP2750675A1 (en) | 2011-08-31 | 2014-07-09 | Novartis AG | Synergistic combinations of pi3k- and mek-inhibitors |
| AU2012354094C1 (en) | 2011-12-15 | 2015-10-15 | Novartis Ag | Use of inhibitors of the activity or function of PI3K |
| AP3834A (en) * | 2012-03-14 | 2016-09-30 | Lupin Ltd | Heterocyclyl compounds |
| US20150141470A1 (en) | 2012-05-08 | 2015-05-21 | The Broad Institute, Inc. | Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy |
| EP3495367B1 (en) | 2012-06-13 | 2020-09-30 | Incyte Holdings Corporation | Substituted tricyclic compounds as fgfr inhibitors |
| WO2014026125A1 (en) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Pyrazine derivatives as fgfr inhibitors |
| WO2014039375A1 (en) | 2012-09-04 | 2014-03-13 | Glaxosmithkline Llc | Method of adjuvant cancer treatment |
| CN104812391A (zh) * | 2012-10-25 | 2015-07-29 | 葛兰素史克公司 | 组合 |
| TR201806682T4 (tr) | 2012-11-29 | 2018-06-21 | Novartis Ag | Farmasötik kombinasyonlar. |
| EA028246B1 (ru) * | 2012-11-30 | 2017-10-31 | ГЛЭКСОСМИТКЛАЙН ЭлЭлСи | Фармацевтическая композиция |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| EP2752191A1 (en) | 2013-01-07 | 2014-07-09 | Sanofi | Compositions and methods using hdm2 antagonist and mek inhibitor |
| KR20150103735A (ko) | 2013-01-09 | 2015-09-11 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | 조합물 |
| EP2963114B1 (en) | 2013-02-27 | 2018-12-12 | Daiichi Sankyo Company, Limited | Method for predicting responsiveness to compound inhibiting mapk signal transduction pathway |
| DK2986610T5 (en) | 2013-04-19 | 2018-12-10 | Incyte Holdings Corp | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS |
| TW201536292A (zh) | 2013-05-28 | 2015-10-01 | Glaxosmithkline Ip No 2 Ltd | 癌症治療方法 |
| BR112015028326A8 (pt) | 2013-06-03 | 2018-01-23 | Novartis Ag | combinações de anticorpo anti-pd-l1, inibidor de mek e/ou inibidor de braf, seus kits e seus usos, e composição farmacêutica |
| WO2015056180A1 (en) | 2013-10-15 | 2015-04-23 | Glaxosmithkline Intellectual Property (No.2) Limited | Indoline derivatives as inhibitors of perk |
| BR112016007396B1 (pt) * | 2013-10-25 | 2021-01-19 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Composto de fórmula (ii), seu processo de preparação e seu uso, composto de fórmula(iia) e composição farmacêutica |
| WO2015059677A1 (en) | 2013-10-26 | 2015-04-30 | Glaxosmithkline Intellectual Property (No.2) Limited | Methods of treating cancer |
| CN104918937B (zh) * | 2013-12-06 | 2016-09-14 | 杭州普晒医药科技有限公司 | 曲美替尼及其溶剂化物的晶型、其制备方法、含有它们的药物组合物及其用途 |
| CA2933311A1 (en) | 2013-12-12 | 2015-06-18 | Novartis Ag | Combinations of trametinib, panitumumab and dabrafenib for the treatment of cancer |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
| EP2913048A1 (en) * | 2014-02-27 | 2015-09-02 | ratiopharm GmbH | Pharmaceutical composition comprising trametinib |
| KR102442436B1 (ko) | 2014-03-14 | 2022-09-15 | 노파르티스 아게 | Lag-3에 대한 항체 분자 및 그의 용도 |
| WO2016009306A1 (en) | 2014-07-15 | 2016-01-21 | Lupin Limited | Heterocyclyl compounds as mek inhibitors |
| WO2016011160A1 (en) | 2014-07-15 | 2016-01-21 | Genentech, Inc. | Compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors |
| WO2016035008A1 (en) | 2014-09-04 | 2016-03-10 | Lupin Limited | Pyridopyrimidine derivatives as mek inhibitors |
| JP6681905B2 (ja) | 2014-09-13 | 2020-04-15 | ノバルティス アーゲー | Ａｌｋ阻害剤の併用療法 |
| KR20170066546A (ko) | 2014-10-03 | 2017-06-14 | 노파르티스 아게 | 조합 요법 |
| WO2016055935A1 (en) | 2014-10-06 | 2016-04-14 | Glaxosmithkline Intellectual Property (No.2) Limited | Combination of lysine-specific demethylase 1 inhibitor and thrombopoietin agonist |
| EA201790834A1 (ru) | 2014-10-14 | 2018-01-31 | Новартис Аг | Молекулы антител к pd-l1 и их применение |
| WO2016059602A2 (en) | 2014-10-16 | 2016-04-21 | Glaxo Group Limited | Methods of treating cancer and related compositions |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| WO2016100882A1 (en) | 2014-12-19 | 2016-06-23 | Novartis Ag | Combination therapies |
| WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| CR20170390A (es) | 2015-02-20 | 2017-10-23 | Incyte Holdings Corp | Heterociclos biciclicos como inhibidores de fgfr |
| JP2016155776A (ja) * | 2015-02-24 | 2016-09-01 | 学校法人兵庫医科大学 | 抗腫瘍効果増強剤および抗腫瘍剤 |
| CZ2015278A3 (cs) | 2015-04-24 | 2016-11-02 | Zentiva, K.S. | Krystalické formy trametinibu |
| EP3316902A1 (en) | 2015-07-29 | 2018-05-09 | Novartis AG | Combination therapies comprising antibody molecules to tim-3 |
| ES2878188T3 (es) | 2015-07-29 | 2021-11-18 | Novartis Ag | Terapias de combinación que comprenden moléculas de anticuerpos contra LAG-3 |
| US20180222982A1 (en) | 2015-07-29 | 2018-08-09 | Novartis Ag | Combination therapies comprising antibody molecules to pd-1 |
| CN108135905A (zh) | 2015-08-28 | 2018-06-08 | 诺华股份有限公司 | 用于治疗癌症的cdk4/6抑制剂lee011、mek1/2抑制剂曲美替尼以及可任选还包括pi3k抑制剂byl719的组合 |
| AU2016314082B2 (en) | 2015-08-28 | 2019-07-25 | Novartis Ag | Mdm2 inhibitors and combinations thereof |
| MA43186B1 (fr) | 2015-11-03 | 2022-03-31 | Janssen Biotech Inc | Anticorps se liant spécifiquement à pd-1 et leurs utilisations |
| RU2605400C1 (ru) * | 2015-11-13 | 2016-12-20 | ЗАО "Р-Фарм" | ПРОИЗВОДНЫЕ 1-(3-АМИНОФЕНИЛ)-6,8-ДИМЕТИЛ-5-(4-ИОД-2-ФТОР-ФЕНИЛАМИНО)-3-ЦИКЛОПРОПИЛ-1H,6H-ПИРИДО[4,3-d]ПИРИМИДИН-2,4,7-ТРИОНА В КАЧЕСТВЕ ИНГИБИТОРОВ МЕК1/2 |
| WO2017098421A1 (en) | 2015-12-08 | 2017-06-15 | Glaxosmithkline Intellectual Property Development Limited | Benzothiadiazine compounds |
| WO2017106656A1 (en) | 2015-12-17 | 2017-06-22 | Novartis Ag | Antibody molecules to pd-1 and uses thereof |
| JP7085985B2 (ja) | 2016-03-04 | 2022-06-17 | 大鵬薬品工業株式会社 | 悪性腫瘍治療用製剤及び組成物 |
| US11883404B2 (en) | 2016-03-04 | 2024-01-30 | Taiho Pharmaceuticals Co., Ltd. | Preparation and composition for treatment of malignant tumors |
| WO2017153952A1 (en) | 2016-03-10 | 2017-09-14 | Glaxosmithkline Intellectual Property Development Limited | 5-sulfamoyl-2-hydroxybenzamide derivatives |
| EP3515446B1 (en) | 2016-09-19 | 2023-12-20 | Novartis AG | Therapeutic combinations comprising a raf inhibitor and a erk inhibitor |
| RU2627692C1 (ru) * | 2016-10-10 | 2017-08-10 | Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм") | N-{ 3-[3-циклопропил-5-(2-фторо-4-иодофениламино)-6,8-диметил-2,4,7-триоксо-3,4,6,7-тетрагидро-2Н-пиридо[4,3-d]пиримидин-1-ил]-фенил} -циклопропанкарбоксамида диметилсульфоксида сольват в качестве ингибитора МЕК1/2 |
| CN107970246B (zh) * | 2016-10-21 | 2020-08-28 | 中山大学 | 非甾体类抗炎药在提高肿瘤细胞对酪氨酸激酶抑制剂的敏感性中的应用 |
| WO2018092064A1 (en) | 2016-11-18 | 2018-05-24 | Novartis Ag | Combinations of mdm2 inhibitors and bcl-xl inhibitors |
| HUE052854T2 (hu) | 2016-11-25 | 2021-05-28 | Genuv Inc | Készítmény a neurális õssejtek differenciálódásának elõsegítésére és védelmére, továbbá módszer a neurális regeneráció indukálására ugyanennek a segítségével |
| CA3045752A1 (en) | 2016-12-01 | 2018-06-07 | Glaxosmithkline Intellectual Property Development Limited | Methods of treating cancer |
| DK3618875T3 (da) | 2017-05-02 | 2023-07-10 | Novartis Ag | Kombinationsterapi omfattende en raf-inhibitor og trametinib |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| TW201922721A (zh) | 2017-09-07 | 2019-06-16 | 英商葛蘭素史克智慧財產發展有限公司 | 化學化合物 |
| WO2019053617A1 (en) | 2017-09-12 | 2019-03-21 | Glaxosmithkline Intellectual Property Development Limited | CHEMICAL COMPOUNDS |
| MX2020004756A (es) | 2017-11-16 | 2020-08-20 | Novartis Ag | Terapias de combinacion. |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| KR102473372B1 (ko) | 2018-03-19 | 2022-12-05 | 다이호야쿠힌고교 가부시키가이샤 | 알킬황산나트륨을 포함하는 의약 조성물 |
| WO2019180141A1 (en) | 2018-03-23 | 2019-09-26 | Bayer Aktiengesellschaft | Combinations of rogaratinib |
| CN111936141A (zh) | 2018-03-30 | 2020-11-13 | 诺华股份有限公司 | 包含达拉菲尼、曲美替尼和erk抑制剂的三重药物组合 |
| EP3560516A1 (en) | 2018-04-27 | 2019-10-30 | Bergen Teknologioverforing AS | Combination therapy including beta-sitosterol in combination with at least one of a braf inhibitor, a mek inhibitor or an erk inhibitor and methods and use thereof |
| CN112566912A (zh) | 2018-05-04 | 2021-03-26 | 因赛特公司 | Fgfr抑制剂的盐 |
| US11466004B2 (en) | 2018-05-04 | 2022-10-11 | Incyte Corporation | Solid forms of an FGFR inhibitor and processes for preparing the same |
| AU2019274657A1 (en) | 2018-05-24 | 2020-12-10 | Janssen Biotech, Inc. | PSMA binding agents and uses thereof |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| WO2020079581A1 (en) | 2018-10-16 | 2020-04-23 | Novartis Ag | Tumor mutation burden alone or in combination with immune markers as biomarkers for predicting response to targeted therapy |
| CN109320513B (zh) * | 2018-11-09 | 2021-03-16 | 安庆奇创药业有限公司 | 一种合成曲美替尼的方法 |
| CA3120352A1 (en) | 2018-11-20 | 2020-05-28 | Nflection Therapeutics, Inc. | Thienyl-aniline compounds for treatment of dermal disorders |
| US11572344B2 (en) | 2018-11-20 | 2023-02-07 | Nflection Therapeutics, Inc. | Cyanoaryl-aniline compounds for treatment of dermal disorders |
| US12378240B2 (en) | 2018-11-20 | 2025-08-05 | Nflection Therapeutics, Inc. | Naphthyridinone-aniline compounds for treatment of dermal disorders |
| JP7406556B2 (ja) | 2018-11-30 | 2023-12-27 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | Ｈｉｖ療法に有用な化合物 |
| BR112021011874A2 (pt) | 2018-12-20 | 2021-09-08 | Novartis Ag | Regime de dosagem e combinação farmacêutica compreendendo derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona |
| WO2020161654A1 (en) * | 2019-02-06 | 2020-08-13 | Aurobindo Pharma Limited | A process for the preparation of trametinib acetic acid solvate |
| WO2020165833A1 (en) | 2019-02-15 | 2020-08-20 | Novartis Ag | 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| AU2020222346B2 (en) | 2019-02-15 | 2021-12-09 | Novartis Ag | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
| US11591395B2 (en) | 2019-04-19 | 2023-02-28 | Janssen Biotech, Inc. | Methods of treating prostate cancer with an anti-PSMA/CD3 antibody |
| KR102881316B1 (ko) | 2019-05-13 | 2025-11-05 | 노파르티스 아게 | 암 치료를 위한 raf 억제제로서의 n-(3-(2-(2-하이드록시에톡시)-6-모르폴리노피리딘-4-일)-4-메틸페닐)-2 (트리플루오로메틸)이소니코틴아미드의 새로운 결정질 형태 |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| TW202114994A (zh) * | 2019-07-29 | 2021-04-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 一種１，６－二氫吡啶－３－甲醯胺衍生物的製備方法 |
| WO2021018941A1 (en) | 2019-07-31 | 2021-02-04 | Glaxosmithkline Intellectual Property Development Limited | Methods of treating cancer |
| US12122767B2 (en) | 2019-10-01 | 2024-10-22 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| GEAP202415945A (en) | 2019-10-14 | 2024-04-25 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| BR112022010664A2 (pt) | 2019-12-04 | 2022-08-16 | Incyte Corp | Derivados de um inibidor de fgfr |
| EP4069696A1 (en) | 2019-12-04 | 2022-10-12 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| CN115175937A (zh) | 2019-12-20 | 2022-10-11 | 诺华股份有限公司 | 用于治疗骨髓纤维化和骨髓增生异常综合征的抗TIM-3抗体MBG453和抗TGF-β抗体NIS793与或不与地西他滨或抗PD-1抗体斯巴达珠单抗的组合 |
| US20230381180A1 (en) * | 2020-01-08 | 2023-11-30 | Icahn School Of Medicine At Mount Sinai | Small molecule modulators of ksr-bound mek |
| US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| TW202140029A (zh) | 2020-02-18 | 2021-11-01 | 瑞士商諾華公司 | 用於治療ｂｒａｆ突變型ｎｓｃｌｃ的包含ｒａｆ抑制劑之治療組合 |
| WO2021206167A1 (ja) | 2020-04-10 | 2021-10-14 | 大鵬薬品工業株式会社 | ３，５－二置換ベンゼンアルキニル化合物とｍｅｋ阻害剤とを用いた癌治療法 |
| WO2021209563A1 (en) | 2020-04-16 | 2021-10-21 | Som Innovation Biotech, S.A. | Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus |
| JP2023525100A (ja) | 2020-05-12 | 2023-06-14 | ノバルティス アーゲー | Ｃｒａｆ阻害剤を含む治療的組み合わせ |
| JP2023528623A (ja) * | 2020-06-02 | 2023-07-05 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | がんを治療するための縮合環化２－アミノ－３－シアノチオフェン及び誘導体 |
| CA3182346A1 (en) | 2020-06-23 | 2021-12-30 | Novartis Ag | Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
| EP4203963A1 (en) | 2020-08-31 | 2023-07-05 | Novartis AG | Combination therapy of a raf inhibitor and a mek inhibitor for the treatment of sarcoma |
| KR20230131189A (ko) | 2020-12-02 | 2023-09-12 | 이케나 온콜로지, 인코포레이티드 | Tead 억제제 및 이의 용도 |
| WO2022120353A1 (en) | 2020-12-02 | 2022-06-09 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
| AU2022210800A1 (en) | 2021-01-25 | 2023-08-10 | Ikena Oncology, Inc. | Combination of a 3-(imidazol-4-yl)-4-(amino)-benzenesulfonamide tead inhibitor with an egfr inhibitor and/or mek inhibitor for use in the treatment of lung cancer |
| PE20240761A1 (es) | 2021-01-28 | 2024-04-17 | Janssen Biotech Inc | Proteinas de union a psma y usos de estas |
| IL304891A (en) | 2021-02-02 | 2023-10-01 | Servier Lab | Selective Protech BCL-XL compounds and methods of use |
| CN117321418A (zh) | 2021-03-18 | 2023-12-29 | 诺华股份有限公司 | 癌症生物标志物及其使用方法 |
| TWI825637B (zh) | 2021-03-31 | 2023-12-11 | 美商輝瑞股份有限公司 | 啶－１，６（２ｈ，７ｈ）－二酮 |
| TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途 |
| JP2024514127A (ja) | 2021-04-09 | 2024-03-28 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗がん剤療法 |
| TW202304459A (zh) | 2021-04-12 | 2023-02-01 | 美商英塞特公司 | 包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法 |
| WO2022221866A1 (en) * | 2021-04-16 | 2022-10-20 | Ikena Oncology, Inc. | Mek inhibitors and uses thereof |
| CN117177752A (zh) | 2021-05-05 | 2023-12-05 | 诺华股份有限公司 | 用于治疗mpnst的化合物和组合物 |
| AR125874A1 (es) | 2021-05-18 | 2023-08-23 | Novartis Ag | Terapias de combinación |
| WO2022259157A1 (en) | 2021-06-09 | 2022-12-15 | Novartis Ag | A triple pharmaceutical combination comprising dabrafenib, trametinib and a shp2 inhibitor |
| JP2024522189A (ja) | 2021-06-09 | 2024-06-11 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤としての三環式ヘテロ環 |
| WO2022261159A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| WO2023114984A1 (en) | 2021-12-17 | 2023-06-22 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
| WO2023166345A2 (en) | 2022-03-02 | 2023-09-07 | Novartis Ag | Precision therapy for the treatment of cancer |
| CN114573581B (zh) * | 2022-03-30 | 2023-09-01 | 沈阳药科大学 | 5-取代氨基-1,3-二取代苯基吡啶并[2,3-d]嘧啶类化合物及其制备与应用 |
| CN114456166B (zh) * | 2022-03-30 | 2023-06-16 | 沈阳药科大学 | 5-取代氨基-3-甲基吡啶并[2,3-d]嘧啶类化合物及其制备与应用 |
| CN114605408B (zh) * | 2022-03-30 | 2023-06-16 | 沈阳药科大学 | 5-羟基-1,3-二取代苯基吡啶并[2,3-d]嘧啶类化合物及其制法和应用 |
| CN114573582B (zh) * | 2022-03-30 | 2023-06-16 | 沈阳药科大学 | 1,2,3,4-四氢吡啶并[2,3-d]嘧啶类化合物及其制备方法和应用 |
| AU2023271885A1 (en) | 2022-05-20 | 2024-12-12 | Les Laboratoires Servier | Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof |
| JP2025517429A (ja) | 2022-05-20 | 2025-06-05 | ノバルティス アーゲー | Ｍｅｔ ｂｃｌ－ｘｌ阻害剤抗体－薬物コンジュゲートおよびその使用の方法 |
| CN114853754B (zh) | 2022-05-23 | 2023-04-18 | 云白药征武科技(上海)有限公司 | 一种硫代酰胺衍生物及其制备方法和应用 |
| CN119768393A (zh) | 2022-05-25 | 2025-04-04 | 医肯纳肿瘤学公司 | Mek抑制剂和其用途 |
| AR129423A1 (es) | 2022-05-27 | 2024-08-21 | Viiv Healthcare Co | Compuestos útiles en la terapia contra el hiv |
| IL322700A (en) | 2023-03-10 | 2025-10-01 | Novartis Ag | Antibody-drug conjugates that inhibit fennerase and methods of using them |
| WO2025111450A1 (en) | 2023-11-22 | 2025-05-30 | Les Laboratoires Servier | Anti-cd74 antibody-drug conjugates and methods of use thereof |
| WO2025132408A2 (en) | 2023-12-21 | 2025-06-26 | Synthon B.V. | Solvates of trametinib |
| WO2025132190A1 (en) | 2023-12-22 | 2025-06-26 | Synthon B.V. | A process for making trametinib |
| WO2025146444A1 (en) | 2024-01-03 | 2025-07-10 | Bayer Aktiengesellschaft | Darolutamide in combination with braf and mek inhibitors for melanoma treatment |
| CN120441478A (zh) * | 2024-02-07 | 2025-08-08 | 成都赜灵生物医药科技有限公司 | 一种六元内酰胺类化合物及其应用 |
| WO2025215536A1 (en) | 2024-04-10 | 2025-10-16 | Novartis Ag | Macrocyclic panras inhibitors for the treatment of cancer |
| CN118121604B (zh) * | 2024-05-07 | 2024-06-25 | 四川成都中农大现代农业产业研究院 | 表没食子儿茶素没食子酸酯的组合物及其作为铜离子载体抗肝癌增敏剂的用途 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3139432A (en) * | 1963-06-24 | 1964-06-30 | Mead Johnson & Co | Pyrido [2, 3-d] pyrimidine-2, 4, 5, 7-tetraones |
| DE4035479A1 (de) * | 1990-11-08 | 1992-05-14 | Basf Ag | Substituierte pyrido (2,3-d)pyrimidin-2,4(1h,3h)-dione |
| KR20010101203A (ko) | 1998-12-15 | 2001-11-14 | 로즈 암스트롱, 크리스틴 에이. 트러트웨인 | Ｍｅｋ 저해제의 이식 조직 거부를 예방하기 위한 용도 |
| KR100609800B1 (ko) | 1998-12-16 | 2006-08-09 | 워너-램버트 캄파니 엘엘씨 | Ｍｅｋ 저해제를 사용한 관절염 치료 방법 |
| HUP0104933A3 (en) | 1999-01-07 | 2003-12-29 | Warner Lambert Co | Antiviral method using mek inhibitors |
| ATE292462T1 (de) | 1999-01-07 | 2005-04-15 | Warner Lambert Co | Behandlung von asthma anhand von mek-inhibitoren |
| HUP0202180A3 (en) | 1999-07-16 | 2004-10-28 | Warner Lambert Co | Method for treating chronic pain using mek inhibitors |
| UA72612C2 (en) | 2000-07-06 | 2005-03-15 | Pyrido[2.3-d]pyrimidine and pyrimido[4.5-d]pyrimidine nucleoside analogues, prodrugs and method for inhibiting growth of neoplastic cells | |
| WO2002006520A1 (en) | 2000-07-19 | 2002-01-24 | Chugai Seiyaku Kabushiki Kaisha | Method of screening compound controlling mek/erk signal transduction and medicinal use of the compound |
| YU2503A (sh) | 2000-07-19 | 2006-05-25 | Warner-Lambert Company | Oksigenovani estri 4-jodo fenilamino benzhidroksamskih kiselina |
| WO2002087620A1 (en) | 2001-04-27 | 2002-11-07 | Chugai Seiyaku Kabushiki Kaisha | Chondrogenesis promoters |
| IL149462A0 (en) | 2001-05-09 | 2002-11-10 | Warner Lambert Co | Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor |
| US6825180B2 (en) * | 2001-05-18 | 2004-11-30 | Cell Therapeutics, Inc. | Pyridopyrimidine compounds and their uses |
| KR20060111716A (ko) * | 2002-01-22 | 2006-10-27 | 워너-램버트 캄파니 엘엘씨 | 2-(피리딘-2-일아미노)-피리도[2,3-ｄ]피리미딘-7-온 |
-
2005
- 2005-06-10 RS RSP-2008/0111A patent/RS50569B/sr unknown
- 2005-06-10 PL PL10013055T patent/PL2298768T3/pl unknown
- 2005-06-10 SI SI200530179T patent/SI1761528T1/sl unknown
- 2005-06-10 SI SI200531629T patent/SI2298768T1/sl unknown
- 2005-06-10 NZ NZ552090A patent/NZ552090A/en not_active IP Right Cessation
- 2005-06-10 MX MXPA06014478A patent/MXPA06014478A/es active IP Right Grant
- 2005-06-10 JP JP2006551659A patent/JP4163738B2/ja not_active Expired - Lifetime
- 2005-06-10 RU RU2007101158/04A patent/RU2364596C2/ru active
- 2005-06-10 ME MEP-2012-138A patent/ME01480B/me unknown
- 2005-06-10 DK DK05751244T patent/DK1761528T3/da active
- 2005-06-10 CN CN2005800266663A patent/CN101006086B/zh not_active Expired - Lifetime
- 2005-06-10 CA CA2727841A patent/CA2727841A1/en not_active Abandoned
- 2005-06-10 PL PL05751244T patent/PL1761528T3/pl unknown
- 2005-06-10 PT PT05751244T patent/PT1761528E/pt unknown
- 2005-06-10 BR BRPI0511967A patent/BRPI0511967B8/pt active IP Right Grant
- 2005-06-10 KR KR1020077000746A patent/KR100883289B1/ko not_active Expired - Lifetime
- 2005-06-10 EP EP07018816A patent/EP1894932A1/en not_active Withdrawn
- 2005-06-10 WO PCT/JP2005/011082 patent/WO2005121142A1/en not_active Ceased
- 2005-06-10 CN CN2010102497650A patent/CN101912400B/zh not_active Expired - Lifetime
- 2005-06-10 EP EP10013055.8A patent/EP2298768B9/en not_active Expired - Lifetime
- 2005-06-10 DE DE602005004286T patent/DE602005004286T2/de not_active Expired - Lifetime
- 2005-06-10 PT PT100130558T patent/PT2298768E/pt unknown
- 2005-06-10 HR HR20080018T patent/HRP20080018T3/xx unknown
- 2005-06-10 DK DK10013055.8T patent/DK2298768T3/da active
- 2005-06-10 ES ES05751244T patent/ES2297723T3/es not_active Expired - Lifetime
- 2005-06-10 AT AT05751244T patent/ATE383360T1/de active
- 2005-06-10 EP EP05751244A patent/EP1761528B1/en not_active Expired - Lifetime
- 2005-06-10 ES ES10013055T patent/ES2397825T3/es not_active Expired - Lifetime
- 2005-06-10 AU AU2005252110A patent/AU2005252110B2/en active Active
- 2005-06-10 CA CA2569850A patent/CA2569850C/en not_active Expired - Lifetime
- 2005-06-10 RS RS20130024A patent/RS52670B/sr unknown
-
2006
- 2006-11-28 IL IL179671A patent/IL179671A0/en active Protection Beyond IP Right Term
-
2007
- 2007-01-09 NO NO20070155A patent/NO338355B1/no active Protection Beyond IP Right Term
-
2008
- 2008-03-19 CY CY20081100312T patent/CY1107253T1/el unknown
- 2008-03-24 JP JP2008076759A patent/JP4913768B2/ja not_active Expired - Lifetime
-
2011
- 2011-10-28 JP JP2011238029A patent/JP5421974B2/ja not_active Expired - Lifetime
-
2012
- 2012-12-12 HR HRP20121020TT patent/HRP20121020T1/hr unknown
-
2013
- 2013-01-07 CY CY20131100020T patent/CY1113538T1/el unknown
-
2014
- 2014-11-10 NL NL300701C patent/NL300701I1/nl unknown
- 2014-11-13 CY CY2014045C patent/CY2014045I2/el unknown
- 2014-11-19 LU LU92602C patent/LU92602I2/xx unknown
- 2014-11-24 FR FR14C0083C patent/FR14C0083I2/fr active Active
-
2016
- 2016-11-24 NO NO2016021C patent/NO2016021I1/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME01480B (me) | DERIVATI 5-AMIN0-2,4,7-TRIOKS0-3,4,7,8-TETRAHIDR0-2H-PIRID0[2,3-d]PIRIMIDINA I SRODNI SPOJEVI, NAMIJENJENI LIJEČENJU RAKA | |
| ES2609595T3 (es) | Fabricación de ácido 2-(5-bromo-4-(4-ciclopropilnaftalen-1-il)-4H-1,2,4-triazol-3-iltio)acético | |
| IL262964A (en) | Preparation of (s)-n-(5-((r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-y l)-3-hydroxypyrrolidine-1-carboxamide | |
| JP2019516795A5 (OSRAM) | ||
| GT200500223A (es) | Polimorfo ii de rapamicina y sus utilizaciones | |
| WO2011113802A3 (en) | Imidazopyridine and purine compounds, compositions and methods of use | |
| EA201791941A1 (ru) | Бициклические кетосульфонамидные соединения | |
| JP2016523256A5 (OSRAM) | ||
| NZ600881A (en) | Pyrazole derivatives as jak inhibitors | |
| MX2010008101A (es) | Derivados de indol 2-carboxamidas y de azaindol 2-carboxamidas sustituidos con un silanilo, su preparacion y su aplicacion en terapeutica. | |
| AR073551A1 (es) | Pirimidinas macrociclicas como inhibidores de proteina cinasa | |
| AU2014284224B2 (en) | Free base crystals | |
| JP6123097B2 (ja) | チエノピリミジン化合物を製造するための方法 | |
| CR20250329A (es) | Compuestos tricíclicos para el tratamiento del cáncer | |
| FR2998298B1 (fr) | Synthese de sels d’imidazo[1,2-a]pyrazin-4-ium pour la synthese du 1,4,7-triazacyclononane (tacn) et de ses derives n- et/ou c-fonctionnalises | |
| JP2018530610A (ja) | ピロロピリミジンキナーゼ阻害剤の薬学的塩、物理的形態、および組成物、ならびにそれらを作製する方法 | |
| JP2020516682A (ja) | ピロロピリミジンキナーゼの薬学的な塩、物理的形態および組成物、ならびにその作製方法 | |
| AR065333A1 (es) | Antagonistas del receptor de dopamina 2 de rapida disociacion | |
| MX2015014353A (es) | Derivados de 2-fenil- o 2-hetaril-imidazol[1,2-a]piridina. | |
| CR20210513A (es) | Compuestos de haxahidro 1-h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria | |
| MX384765B (es) | [8-(fenilsulfonil)-3,8-diazabiciclo[3.2.1]oct-3-il](1h-1,2,3-triazol-4-il)metanonas. | |
| JP2014520785A5 (OSRAM) | ||
| HRP20241312T1 (hr) | Derivati n-(imidazo[1,2-b]piridazin-3-il)-1-cikloheksil-2h-indazol-5-karboksamida i n-(pirazolo[1,5-a]pirimidin-3-il)-1-cikloheksil-2h-indazol-5-karboksamida kao inhibitori irak4 za liječenje astme | |
| EP4424370A3 (en) | 7-phenoxy-n-(3-azabicyclo[3.2.1loctan-8-yl)-6,7-dihydro-5h-pyrrolo[1,2-b][1,2,4]triazol-2-amine derivatives and related compounds as gamma-secretase modulators for the treatment of alzheimer's disease | |
| AR074866A1 (es) | 2-amino-pirimidinas 4,6-disustituidas como modulador del receptor h4 de histamina |